Mirum Pharmaceuticals, Inc. $MIRM Stake Boosted by Next Century Growth Investors LLC

Next Century Growth Investors LLC increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 368,035 shares of the company’s stock after buying an additional 7,101 shares during the period. Mirum Pharmaceuticals comprises 2.0% of Next Century Growth Investors LLC’s investment portfolio, making the stock its 9th biggest holding. Next Century Growth Investors LLC’s holdings in Mirum Pharmaceuticals were worth $29,071,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MIRM. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $32,000. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MIRM shares. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and issued a $132.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Raymond James Financial restated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $138.36.

Mirum Pharmaceuticals Stock Down 0.2%

MIRM stock opened at $99.35 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The company’s 50 day moving average is $97.89 and its 200 day moving average is $91.13. The stock has a market cap of $6.06 billion, a price-to-earnings ratio of -7.30 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a 1-year low of $47.89 and a 1-year high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.30) earnings per share. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This represents a 27.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Peter Radovich sold 16,515 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the completion of the sale, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at approximately $3,704,218.56. This represents a 29.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 111,806 shares of company stock valued at $10,408,916 over the last 90 days. Company insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.